NCT01502501WithdrawnNot Applicable
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Cardiovascular Effects of Intramyocardial and Intravenous Implantation of Autologous Adipose-Derived Stem Cells in Non-Ischemic Congestive Heart Failure Patients
Ageless Regenerative Institute1 site in 1 countryStarted: May 1, 2011Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Withdrawn
- Sponsor
- Locations
- 1
- Primary Endpoint
- Minnesota Living with Heart Failure Quality of Life Questionnaire
Study Overview
Brief Summary
The intent of this clinical study is to answer the questions:
- Is the proposed treatment safe
- Is treatment effective in improving the disease pathology of patients with Heart Disease as assessed by a series of measurements indicating improvement, stability, or degradation of a patient's cardiovascular function and exercise capacity?
Detailed Description
This will be an open-label, non-randomized, multi-center patient-sponsored study designed to assess the safety and cardiovascular effects of Adipose-derived Stem Cell (ASC) implantation using a catheter delivery system in patients who have nonischemic congestive heart failure. A percutaneous transluminal endomyocardial injection catheter will be used for delivery of ASCs. The therapy is composed of cells isolated from a patient's own adipose tissue. Liposuction will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Willing and able to sign informed consent
- •Age >18 years and < 80 years
- •NYHA Class II-IV
- •Congestive Heart Failure without an acute coronary syndrome during the prior 6 months
- •LVEF less than or equal to 40% measured by echocardiography at both local and investigative sites, AND
- •Left ventricular wall without mural thrombus and of thickness greater than 0.5 cm
- •No significant valvular disease including: Moderate-to-severe mitral regurgitation (3-4+), aorticstenosis (valve area <1.5 cm2), aortic insufficiency (3-4+)
- •Up to date on all age and gender appropriate cancer screening per American Cancer Society
Exclusion Criteria
- •Limiting symptoms due to non-CHF causes, such as lung disease, peripheral vascular disease, arthritis or other musculoskeletal disorders
- •Inability to complete a 6-minute walk test for any reason
- •Need for intravenous CHF medications, chronic continuous oxygen therapy or oral steroids,
- •Coronary Artery Bypass Surgery (CABG) surgery within 60 days prior to screening
- •Planned revascularization within 4 months following enrollment
- •Aortic aneurysm or dilatation (>3.8 cm by echocardiography or other imaging modality)
- •Peripheral vascular disease at or below the distal aorta that may interfere with catheter use
- •Hemodynamically significant pericardial disease
- •Prior aortic or mitral valve replacement
- •Biventricular pacing device implant within the last 3 months OR whose device is scheduled to be revised following enrollment in this trial
- •Scheduled to receive or history of cardiac transplant, surgical remodeling procedure, left ventricular assist device
- •Stroke within 180 days of screening
- •Positive pregnancy test in women of child bearing potential or who are unwilling to use an acceptable method of contraception.
- •Drug or alcohol dependence
- •Life expectancy of less than 1 year
- •History of cancer (other than non-melanoma skin cancer or in situ cervical cancer) in the last five years
- •Exposure to angiogenic therapy (including myocardial laser) or another investigational drug within 60 days of screening, or enrollment in any concurrent study that may confound the results of this study
- •Any factors in the opinion of the Investigator which render the patient unsuitable for participation, that will interfere with conduct of the study or interpretation of the results.
Outcomes
Primary Outcomes
Minnesota Living with Heart Failure Quality of Life Questionnaire
Time Frame: 6 months
Number of Adverse Events
Time Frame: 6 months
Improvement in 6 minute walk test
Time Frame: 6 months
Improvement in 6 minute walk test
Time Frame: 3 months
compared to baseline
Minnesota Living with Heart Failure Quality of Life Questionnaire
Time Frame: 3 months
Secondary Outcomes
- Improvement in New York Heart Association (NYHA) classification(6 months)
- Improvement in the Left Ventricular Ejection Fraction (LVEF)(6 months)
- Improvement in the Left Ventricular (LV) Volume(6 months)
- Improvement in New York Heart Association (NYHA) classification(3 months)
- Improvement in the Left Ventricular Ejection Fraction (LVEF)(3 months)
- Improvement in the Left Ventricular (LV) Volume(3 months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Withdrawn
Not Applicable
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stem Cells in Patients With Frailty SyndromeFrailty SyndromeNCT01501461Ageless Regenerative Institute
Withdrawn
Not Applicable
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple SclerosisAutoimmune Diseases of the Nervous SystemAutoimmune DiseasesNervous System DiseasesMultiple SclerosisNCT01453764Ageless Regenerative Institute
Withdrawn
Phase 1
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients After StrokeStrokeNCT01453829Ageless Regenerative Institute
Withdrawn
Not Applicable
Study to Assess the Safety and Effects of Autologous Adipose-Derived SVF Cells in Patients With Parkinson's DiseaseParkinson's DiseaseNCT01453803Ageless Regenerative Institute
Withdrawn
Not Applicable
Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Diffuse Lesions in the BrainBrain Lesion (General)NCT01453777Ageless Regenerative Institute